H1テキスト

  • TEL03-3353-1211
  • FAX03-3353-4707

〒160-8582 東京都新宿区信濃町35 慶應義塾大学MAP

お問い合わせ

MENU

スタッフ紹介

お問い合わせ

専任講師

茂田 浩平

茂田 浩平
一般・消化器外科の中でも大腸・小腸疾患における外科治療を専門としております。腹腔鏡手術，ロボット支援下手術を駆使した低侵襲手術、根治性の高い手術治療を目指しています。また、癌などの悪性腫瘍だけではなく、炎症性腸疾患や良性疾患に対する手術治療も積極的に行っております。患者さんへの丁寧な説明を心がけておりますので、お気軽にご相談ください。

  • 日本外科学会専門医
  • 日本消化器外科学会専門医・指導医
  • 日本内視鏡外科学会技術認定医(大腸)
  • 日本大腸肛門病学会専門医

経歴

2006年 独立行政法人国立病院機構東京医療センター　初期臨床研修医
2008年 慶應義塾大学医学部外科学教室　入局
大和市立病院　外科
2009年 佐野厚生総合病院　外科
2010年 慶應義塾大学医学部　一般・消化器外科
2013年 さいたま市立病院　外科
2014年 慶應義塾大学医学部　学位(博士)　取得
2015年 慶應義塾大学医学部　一般・消化器外科　助教
2016年 米国Massachusetts General Hospital, Radiation Oncology, Harvard Medical School　Research Fellow
2018年 慶應義塾大学医学部　一般・消化器外科　助教
2022年 慶應義塾大学医学部　一般・消化器外科　専任講師

主たる研究内容

  • 大腸癌・炎症性腸疾患に対する手術治療成績の向上
  • 大腸癌における化学療法の効果予測および効果促進因子の検討
  • 腫瘍微小環境と腫瘍免疫の関連性の検討

資格

  • 日本外科学会専門医
  • 日本消化器外科学会専門医・指導医
  • 日本内視鏡外科学会技術認定医(大腸)
  • 消化器がん外科治療認定医
  • 日本がん治療認定医機構がん治療認定医
  • ロボット手術(ダヴィンチ)トレーニングコース修了
  • 日本大腸肛門病学会専門医

受賞歴

2023年 第123回日本外科学会 優秀演題賞
2022年 第60回日本癌治療学会 Young Oncologist Award
2021年 消化器外科学会 Young Investigator Award
刀林奨励賞
2016年

第18回前田賞

助成金

2020年 文部科学省科学研究費　若手研究「大腸癌におけるマルチキナーゼ阻害薬の腫瘍微小環境と腫瘍免疫への作用の検討」
2017年 上原生命科学財団　海外留学助成金リサーチフェローシップ
2011年

文部科学省科学研究費　若手研究(B)

「大腸癌細胞膜表面EGFR検出によるCetuximab感受性予測法の開発」

論文

  • 1. Kato H, Seishima R, Matsui S, Shigeta K, Okabayashi K, Kitagawa Y. Characteristic Changes of Ulcerative Colitis-Associated Neoplasm Patients in the Era of Biologics: a 20-Year Single Institution Experience of Surgical Cases. J Gastrointest Surg. 2023 Nov 8.
  • 2. Okui J, Shigeta K, Kato Y, Mizuno S, Sugiura K, Seo Y, Nakadai J, Baba H, Kikuchi H, Hirata A, Makino A, Kondo T, Matsui S, Seishima R, Okabayashi K, Obara H, Sato Y, Kitagawa Y. Delayed-Onset Organ/Space Surgical Site Infection Worsens Prognosis in High-Risk Stage II and III Colorectal Cancer. J Gastrointest Surg. 2023 Sep 22.
  • 3. Kato H, Seishima R, Nakamura K, Matsui S, Shigeta K, Okabayashi K, Kitagawa Y. The Prognostic Nutritional Index is a Predictive Marker for Postoperative Complications in Patients with Late-Onset Ulcerative Colitis. World J Surg. 2023 Jul 20.
  • 4. Sakamoto K, Okabayashi K, Matsumoto S, Matsui S, Seishima R, Shigeta K, Kitagawa Y. Drainage pattern of the splenic flexure vein and its accompanying arteries using three-dimensional computed tomography angiography: a single-centre study of 600 patients. Colorectal Dis. 2023 May 23.
  • 5. Sugiura K, Seo Y, Tajima Y, Kikuchi H, Hirata A, Nakadai J, Baba H, Kondo T, Makino A, Kato Y, Matsui S, Seishima R, Shigeta K, Okabayashi K, Kitagawa Y. Prognostic Impact of Main Lymph Node Metastasis in Patients with Colon Cancer. World J Surg. 2023 Jan 23.
  • 6. Sasaki T, Shigeta K, Matsui S, Seishima R, Okabayashi K, Kitagawa Y. Mesenteric location of lymph node metastasis for colorectal cancer. ANZ J Surg. 2023.
  • 7. Sasaki T, Shigeta K, Kitahara S, Suzuki Y, Matsui S, Seishima R, Okabayashi K, Duda DG, Kitagawa Y. Inhibition of STAT3 Promotes Effector T Cell Infiltration But also Immunosuppression in the HCC Tumor Microenvironment. Anticancer Res. 2022 Nov;42(11):5205-5215.
  • 8. Sakamoto K, Okabayashi K, Matsui S, Seishima R, Shigeta K, Kitagawa Y. Association of Tumor Pathological Response with the Use of Metformin During Neoadjuvant Chemoradiotherapy in Rectal and Esophageal/Gastroesophageal Cancer Patients: a Systematic Review and Meta-analysis. J Gastrointest Surg. 2022 Jul.
  • 9. Ogiri M, Seishima R, Nakamura K, Aimono E, Matsui S, Shigeta K, Chiyoda T, Tanishima S, Okabayashi K, Nishihara H, Kitagawa Y. Real-world application of next-generation sequencing-based test for surgically resectable colorectal cancer in clinical practice. Future Oncol. 2022 Jul. 
  • 10. Sugiura K, Okabayashi K, Seishima R, Ishida T, Shigeta K, Tsuruta M, Hasegawa H, Kitagawa Y. Metformin inhibits the development and metastasis of colorectal cancer. Med Oncol. 2022 Jul ;39(9):136.
  • 11. Kato Y, Shigeta K, Tajima Y, Kikuchi H, Hirata A, Nakadai J, Sugiura K, Seo Y, Kondo T, Okui J, Matsui S, Seishima R, Okabayashi K, Kitagawa Y. Comprehensive risk score of the E-PASS as a prognostic indicator for patients after elective and emergency curative colorectal cancer surgery: A multicenter retrospective study. 2022 Apr 18;101.
    • 12. Nakamura K, Seishima R, Emoto K, Kawahara T, Matsui S, Shigeta K, Okabayashi K, Hosoe N, Kitagawa Y. The development of colon adenocarcinoma on a ganglioneuroma in a patient with nonhereditary disease. Am J Gastroenterol. 2022.
    • 13. Mizuno S, Okabayashi K, Ikebata A, Matsui S, Seishima R, Shigeta K, Kitagawa Y. Prediction of pouchitis after ileal pouch-anal anastomosis in patients with ulcerative colitis using artificial intelligence and deep learning. Tech Coloproctol. 2022.
    • 14. Nakamura K, Seishima R, Matsui S, Shigeta K, Okabayashi K, Kitagawa Y. The prognostic impact of preoperative mean corpuscular volume in colorectal cancer. Jpn J Clin Oncol. 2022.
    • 15. Mizuno S, Seishima R, Yamasaki J, Hattori K, Ogiri M, Matsui S, Shigeta K, Okabayashi K, Nagano O, Li L, Kitagawa Y. Angiopoietin-like 4 promotes glucose metabolism by regulating glucose transporter expression in colorectal cancer. J Cancer Res Clin Oncol. 2022.
    • 16. Tsunoda J, Shigeta K, Matsui S, Seishima R, Okabayashi K, Kitagawa Y. Neutrophil-to-Lymphocyte Ratio is a Useful Biomarker for Predicting Postoperative Complications in Crohn's Disease. J Gastrointest Surg. 2022.
    • 17. Morita S, Tsuruta M, Okabayashi K, Shigeta K, Seishima R, Monno M, Itano O, Kitagawa Y. Evaluation of abdominal aortic calcification by plain CT predicts anastomotic leakage in laparoscopic surgery for colorectal cancer. Jpn J Clin Oncol. 2021.
    • 18. Suzumura H, Tsuruta M, Okabayashi K, Shigeta K, Seishima R, Ishida T, Shimada T, Asada Y, Koishikawa K, Akimoto S, Itano O, Hasegawa H, Kitagawa Y. BAF57 Is a Potential Determinant of Colorectal Cancer Malignancy. Anticancer Res. 2021;41(11):5445-5452.
    • 19. Ikebata A, Okabayashi K, Tsuruta M, Shigeta K, Seishima R, Shimoda M, Naganuma M, Kitagawa Y. Colectomy risk score predicts pouchitis in patients with ulcerative colitis. Updates Surg. 2021.
    • 20. Matsuoka S, Kondo T, Seishima R, Okabayashi K, Tsuruta M, Shigeta K, Ishida T, Hasegawa H, Kitagawa Y. Surgical glove perforation during laparoscopic colorectal procedures . Surg Endosc. 2021;11:1-6.
    • 21. Sasaki T, Shigeta K, Okabayashi K, Tsuruta M, Seishima R, Matsui S, Kitagawa Y. Horizontal spread of pericolic lymph node metastasis as a prognostic factor for recurrence in Stage Ⅲ colorectal cancer. Colorectal Dis. 2021;23(6):1370-1378.
    • 22. Morita S, Tsuruta M, Okabayashi K, Ishida T, Shigeta K, Seishima R, Itano O, Hasegawa H, Kitagawa Y. Impact of intraoperative hypocapnia on postoperative complications in laparoscopic surgery for colorectal cancer. Surg Today. 2021.
    • 23. Kato Y, Shigeta K, Okabayashi K, Tsuruta M, Seishima R, Matsui S, Sasaki K, Koseki Y, Kitagawa Y. Lymph noge metastasis is strongly associated with lung metastasis as the first recurrence site in colorectal cancer. Surgery. 2021;S0039-6060(21).
    • 24. Asada Y, Tsuruta M, Okabayashi K, Shigeta K, Ishida T, Shimada T, Suzumura H, Koishikawa K, Akimoto S, Hasegawa H, Kitagawa Y. Inhibition of Heat-shock Protein 27 Reduces 5-Fluorouracil-acquired Resistance in Human Colon Cancer Cells. Anticancer Res. 2021;41(3):1283-1290.
    • 25. Seishima R, Miyata H, Okabayashi K, Hasegawa H, Tsuruta M, Shigeta K, Monno M, Yamashita Y, Inomata M, Wakabayashi G, Kakeji Y, Kitagawa Y, Watanabe M. Safety and feasibility of laparoscopic surgery for elderly cancer patients in Japan：a nationwide study. BJS Open. 2021;5(2).
    • 26. Mizuno S, Seishima R, Okabayashi K, Shigeta K, Matsui S, Kitagawa Y. Sarcopenic obesity is a postoperative prognostic factor for stage Ⅱ and Ⅲ colorectal cancer. J Gastrointest Surg. 2021.
    • 27. Aoki S, Inoue K, Klein S, Halvorsen S, Chen J, Matsui A, Nikmaneshi MR, Kitahara S, Hato T, Chen X, Kawakubo K, Nia HT, Chen I, Schanne DH, Mamessier E, Shigeta K, Kikuchi H, Ramjiawan RR, Schmidt TC, Iwasaki M, Yau T, Hong TS, Quaas A, Plum PS, Dima S, Popescu I, Bardeesy N, Munn LL, Borad MJ, Sassi S, Jain RK, Zhu AX, Duda DG. Placental growth factor promotes tumour desmoplasia and treatment resistance in intrahepatic cholangiocarcinoma. Gut. 2021.
    • 28. Shigeta K, Matsui A, Kikuchi H, Klein S, Mamessier E, Chen I, Aoki S, Kitahara S, Inoue K, Shigeta A, Hato T, Ramjiawan R, Staiculescu D, Zopf D, Fiebig L, Hobbs G, Quaas A, Dima S, Popescu I, Huang P, Munn L, Cobbold M, Goyal L, Zhu A, Jain R, Duda D. Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma. J Immunother Cancer. 2020;8(2).
    • 29. Ikebata A, Okabayashi K, Tsuruta M, Shigeta K, Seishima R, Naganuma M, Kitagawa Y. The utility of the colectomy risk score in terms of predicting postoperative complications in patients with ulcerative colitis. J Gastrointest Surg. 2020.
    • 30. Makino A, Tsuruta M, Okabayashi K, Ishida T, Shigeta K, Seishima R, Ikebata A, Koishikawa K, Hasegawa H, Shimoda M, Fukunaga K, Betsuyaku T, Kitagawa Y. The Impact of Smoking on Pulmonary Metastasis in Colorectal Cancer. Onco Targets Ther. 2020;13:9623-9629.
    • 31. Shigeta K, Datta M, Hato T, Kitahara S, Chen I, Matsui A, Kikuchi H, Mamessier E, Aoki S, Ramjiawan R, Ochiai H, Bardeesy N, Huang P, Cobbold M, Zhu A, Jain R, Duda D. Dual programmed death receptor-1 and vascular endothelial growth factor receptor-2 blockade promotes vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma. Hepatology. 2020;71(4):1247-1261.
    • 32. Millar DG, Ramjiawan RR, Kawaguchi K, Gupta N, Chen J, Zhang S, Nojiri T, Ho WW, Aoki S, Jung K, Chen I, Shi F, Heather JM, Shigeta K, Morton LT, Sepulveda S, Wan L, Joseph R, Minogue E, Khatri A, Bardia A, Ellisen LW, Corcoran RB, Hata AN, Pai SI, Jain RK, Fukumura D, Duda DG, Cobbold M. Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy. Nat Biotechnol. 2020
    • 33. Shigeta K, Datta M, Hato T, Kitahara S, Chen IX, Matsui A, Kikuchi H, Mamessier E, Aoki S, Ramjiawan RR, Ochiai H, Bardeesy N, Huang P, Cobbold M, Zhu AX, Jain RK, Duda DG. Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma. Hepatology. 2019
    • 34. Matsui S, Okabayashi K, Tsuruta M, Shigeta K, Seishima R, Ishida T, Kondo T, Suzuki Y, Hasegawa H, Shimoda M, Sugimoto S, Sato T, Kitagawa Y. Interleukin-13 and its signaling pathway is associated with obesity-related colorectal tumorigenesis. Cancer Sci. 2019 Jul;110(7):2156-2165.
    • 35. Goyal L, Zheng H, Abrams TA, Miksad R, Bullock AJ, Allen JN, Yurgelun MB, Clark JW, Kambadakone A, Muzikansky A, Knowles M, Galway A, Afflitto AJ, Dinicola CF, Regan E, Hato T, Mamessier E, Shigeta K, Jain RK, Duda DG, Zhu AX. A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma. Clin Cancer Res. 2019 Jan 1;25(1):80-89.
    • 36. Tsuruta M, Hasegawa H, Okabayashi K, Shigeta K, Ishida T, Yahagi M, Ishii Y, Kitagawa Y. Needlescopic versus conventional laparoscopic surgery for colorectal cancer ~a comparative study~. J Anus Rectum Colon. 2018 May 25;1(2):45-49.
    • 37. Shimada T, Tsuruta M, Hasegawa H, Okabayashi K, Shigeta K, Ishida T, Asada Y, Suzumura H, Koishikawa K, Akimoto S, Kitagawa Y. Heat shock protein 27 knockdown using nucleotide‑based therapies enhances sensitivity to 5-FU chemotherapy in SW480 human colon cancer cells. Oncol Rep. 2018 Mar;39(3):1119-1124.
    • 38. Liu H, Naxerova K, Pinter M, Incio J, Lee H, Shigeta K, Ho WW, Crain JA, Jacobson A, Michelakos T, Dias-Santos D, Zanconato A, Hong TS, Clark JW, Murphy JE, Ryan DP, Deshpande V, Lillemoe KD, Fernandez-Del Castillo C, Downes M, Evans RM, Michaelson J, Ferrone CR, Boucher Y, Jain RK. Use of Angiotensin System Inhibitors is Associated with Immune Activation and Longer Survival in Non-Metastatic Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2017 in press
    • 39. Tajima Y, Tsuruta M, Yahagi M, Hasegawa H, Okabayashi K, Shigeta K, Ishida T, Kitagawa Y. Is preoperative spirometry a predictive marker for postoperative complications after colorectal cancer surgery? Jpn J Clin Oncol. 2017 in press
    • 40. Kondo T, Tsuruta M, Hasegawa H, Okabayashi K, Shigeta K, Hayashida T, Kitagawa Y. The use of laparoscopic rectopexy to manage rectal prolapse with Pseudo-Meigs' syndrome in a 64-year-old female: a case report. Clin Case Rep. 2017 Mar 29;5(5):642-644
    • 41. Suzuki Y, Okabayashi K, Hasegawa H, Tsuruta M, Shigeta K, Kondo T, Kitagawa Y. Comparison of Preoperative Inflammation-based Prognostic Scores in Patients With Colorectal Cancer. Ann Surg. 2016 in press.
    • 42. Suzuki Y, Okabayashi K, Hasegawa H, Tsuruta M, Shigeta K, Murakami K, Kitagawa Y. Metabolic Tumor Volume and Total Lesion Glycolysis in PET/CT Correlate With the Pathological Findings of Colorectal Cancer and Allow Its Accurate Staging. Clin Nucl Med. 2016 Oct; 41(10): 761-5.
    • 43. Kondo T, Okabayashi K, Hasegawa H, Tsuruta M, Shigeta K, Kitagawa Y. The impact of hepatic fibrosis on the incidence of liver metastasis from colorectal cancer. Br J Cancer. 2016 Jun 28; 115(1): 34-9.
    • 44. Shigeta K, Hasegawa H, Okabayashi K, Tsuruta M, Ishii Y, Endo T, Ochiai H, Kondo T, Kitagawa Y. Randomized phase II trial of TEGAFIRI (tegafur/uracil, oral leucovorin, irinotecan) compared with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) in patients with unresectable/recurrent colorectal cancer. Int J Cancer. 2016 Aug 15; 139(4): 946-54.
    • 45. Shigeta K, Okabayashi K, Hasegawa H, Tsuruta M, Seishima R, Kitagawa Y. Meta-analysis of laparoscopic surgery for recurrent Crohn’s disease. Surg Today. 2016 Aug; 46(8): 970-8.
    • 46. Shigeta K, Ishii Y, Hasegawa H, Okabayashi K, Kitagawa Y. Clinical Usefulness of 5-FU Metabolic Enzymes as Predictive Markers of Response to Chemotherapy in Colorectal Cancer. World J Surg. 2016 Apr;40(4):1019-20.
    • 47. Shigeta K, Okabayashi K, Baba H, Hasegawa H, Tsuruta M, Yamafuji K, Kubochi K, Kitagawa Y. A meta-analysis of the use of a transanal drainage tube to prevent anastomotic leakage after anterior resection by double-stapling technique for rectal cancer. Surg Endosc. 2016 Feb; 30(2): 543-50.
    • 48. Shigeta K, Baba H, Yamafuji K, Asami A, Takeshima K, Nagasaki K, Okamoto N, Murata T, Arai S, Kubochi K, Kitagawa Y. Effects of laparoscopic surgery on the patterns of death in elderly colorectal cancer patients: competing risk analysis compared with open surgery. Surg Today. 2016 Apr; 46(4): 422-9
    • 49. Seishima R, Okabayashi K, Hasegawa H, Tsuruta M, Shigeta K, Matsui S, Yamada T, Kitagawa Y. Is laparoscopic colorectal surgery beneficial for elderly patients? A systematic review and meta-analysis. J Gastrointest Surg. 2015 Apr;19(4):756-65.
    • 50. Shigeta K, Ishii Y, Hasegawa H, Okabayashi K, Kitagawa Y. Evaluation of 5-Fluorouracil Metabolic Enzymes as Predictors of Response to Adjuvant Chemotherapy Outcomes in Patients with Stage II/III Colorectal Cancer: A Decision-Curve Analysis. World J Surg. 2014 Dec;38(12):3248-56.
    • 51. Shigeta K, Baba H, Yamafuji K, Kaneda H, Katsura H, Kubochi K. Outcomes for patients with obstructing colorectal cancers treated with one-stage surgery using transanal drainage tubes. J Gastrointest Surg. 2014 Aug;18(8):1507-13.
    • 52. Shigeta K, Okabayashi K, Hasegawa H, Ishii Y, Ochiai H, Tsuruta M, Mukai M, Kameyama K, Uraoka T, Yahagi N, Kitagawa Y. Long-term outcome of patients with locally resected high- and low-risk rectal carcinoid tumors. J Gastrointest Surg. 2014 Apr; 18 (4): 768-73.
    • 53. Shigeta K, Hayashida T, Hoshino Y, Okabayashi K, Endo T, Ishii Y, Hasegawa H, Kitagawa Y. Expression of epidermal growth factor receptor detected by cetuximab indicates its efficacy to inhibit in vitro and in vivo proliferation of colorectal cancer cells. PLoS One. 2013 Jun 18;8(6):e66302.
一覧へ戻る

Copyright© 慶應義塾大学医学部外科（一般・消化器外科）腸班.
All rights reserved.